ホーム › クローン病 › テキサス

テキサスにおけるクローン病の臨床試験

テキサス内の拠点で、クローン病に関する35件の研究が参加者を募集しています。

テキサス内の都市

公式研究テキスト（英語）

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

GI Alliance - Digestive Health Associates of Texas - DHAT ( Site 0290), Garland
GI Alliance - Lubbock ( Site 0288), Lubbock
Caprock Gastro Research ( Site 0293), Lubbock
他3件

被験者募集中第3相

全年齢 · 全性別 · 2026/10/02更新 · NCT06651281

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Baylor University Medical Center ( Site 5031), Dallas
Epic Medical Research - Mesquite ( Site 5153), Denton
Baylor College of Medicine Medical Center ( Site 5020), Houston
他6件

被験者募集中第3相

16歳〜80歳 · 全性別 · 2026/10/02更新 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Novel Research - Bellaire /ID# 280925, Bellaire
Ophthalmology Surgery Center of Dallas /ID# 284065, Dallas
Gi Alliance - Texas Digestive Disease Consultants - Fort Worth /ID# 283977, Fort Worth
他9件

被験者募集中第2相

18歳〜75歳 · 全性別 · 2026/10/02更新 · NCT07697456

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

The Clinical Trials Network CTNX LLC, El Paso
Amel Med LLC, Georgetown
Kelsey Research Foundation, Houston
他7件

被験者募集中第4相

18歳〜80歳 · 全性別 · 2026/09/30更新 · NCT06581328

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Cook Childrens Medical Center, Fort Worth

被験者募集中第3相

2歳〜17歳 · 全性別 · 2026/09/25更新 · NCT05923073

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Gi Alliance - Cedar Park /ID# 268153, Cedar Park
Houston Methodist Hospital /ID# 265533, Houston
Caprock Gastro Research - Lubbock /ID# 265541, Lubbock
他3件

被験者募集中第2相

18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06548542

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

DFW Clinical Trials, Carrollton
Lubbock Gastroenterology, Lubbock
Gastroenterology Research of America, LLC, San Antonio
他2件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT07499232

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

The University of Texas at Austin, Austin
DFW Clinical Trials, Carrollton
Baylor University Medical Center, Dallas
他5件

被験者募集中第2/3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT07196722

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Cook Childrens Medical Center, Fort Worth

被験者募集中第3相

3歳以上 · 全性別 · 2026/09/25更新 · NCT06663332

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Novel Research, LLC, Bellaire
One of a Kind Clinical research Center TX LLC, Kingwood
Southern Star Research Institute, LLC, San Antonio
他1件

被験者募集中第2相

18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06233461

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Gastroenterology Research of San Antonio, San Antonio
Southern Star Research Institute, San Antonio
Tyler Research Institute, Tyler

被験者募集中第3相

18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

UT Southwestern Simmons Cancer Center - RedBird, Dallas
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
他2件

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Inquest Clinical Research-Site Number: 8400144, Baytown
The University of Texas Southwestern Medical Center-Site Number: 8400098, Dallas
Valley Institute of Research-Site Number: 8400004, Harlingen
他8件

被験者募集中第3相

16歳〜80歳 · 全性別 · 2026/09/23更新 · NCT07184931